NWPF

News ArchivesRead News

StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study

Wednesday July 23, 2014

StemGenex Registers Clinical Study for Parkinson’s Disease with Clinicaltrials.gov

PR Web - StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study for Parkinson’s disease. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with degenerative diseases.

This clinical study makes stem cell therapy accessible to the millions of individuals currently living with Parkinson’s disease. The protocol used in these stem cell treatments is unique to StemGenex, having the possibility of being more effective than other stem cell treatments currently available. StemGenex has developed a multiple administration protocol for patients suffering from Parkinson’s disease which includes targeted methods of stem cell delivery. Among these methods is a novel approach for delivering stem cells past the blood brain barrier – an issue most stem cell treatments have been challenged by.

Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, “As is the case with most neurodegenerative conditions, there are few available drugs to treat Parkinson’s disease. The handful of drugs that are available can only ameliorate symptoms and unfortunately, prolonged usage can create terrible side-effects. Further, these drugs do not halt disease progression or aid in the repair of established damage. Our goal is to provide regenerative medicine applications that address these critical issues. The study we are conducting is designed to provide us with a large amount of rigorously collected data so that we can better understand the clinical benefit of Parkinson’s patients treated with stem cells.”

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.govand is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, “It is important patients have access to top-tier stem cell therapy. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.”

Rita Alexander, founder and president of StemGenex stated, “Parkinson's disease affects a very small part of the brain but anyone suffering with this disease understands the negative impact on his or her life is very big, actually, enormous. Over the last several years we have observed significant improvement in the symptoms of Parkinson’s patients through stem cell treatment. We are determined to be part of the solution and are eager to document and publish our findings in the next few years.”

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Parkinson’s disease and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple SclerosisAlzheimer’s disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com.

(23 July 2014). PR Web. StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study. http://www.prweb.com/releases/2014/07/prweb12037620.htm

Recent News

Jul 24 - Parkinson's: Mutant gene interaction may pave the way for new treatments
Jul 22 - Boxing training used to fight against Parkinson's disease
Jul 17 - Stem cell treatment breakthrough could cure Parkinson’s patients
Jul 14 - Cancer drug shows early promise for Parkinson's disease
Jul 13 - Opinion: Dividing the Caregiving Responsibilities Between Siblings
Jul 12 - Researchers make advance in possible treatments for Gaucher, Parkinson’s diseases
Jul 11 - Parkinson’s Head Trauma Link Looks Even Stronger
Jul 7 - Penn students’ start-up XEED puts wearables to work against Parkinson’s disease
Jul 5 - Last Patient Enrolled in Pivotal Phase 3 Parkinson’s Disease Trial, Cynapsus Therapeutics Says
Jun 29 - Exoskeleton Could Quell the Tremors of Parkinson's Disease Patients at Crucial Moments
Jun 28 - Parkinson's disease: New protein discovery could fuel new treatments
Jun 27 - Study finds direct evidence linking Parkinson’s to autoimmune disease; 2 genes that are key regulators of immune system discovered
Jun 27 - Blocking key enzyme halts parkinson's disease symptoms in mice
Jun 23 - Parkinson's Research Might Benefit from Novel Discovery of Zinc Transport Protein Structure
Jun 23 - Parkinson's disease breakthrough 'could lead to cure'
Jun 20 - More American men diagnosed with Parkinson's
Jun 15 - First monkey genetically engineered to have Parkinson’s created
Jun 14 - Fighting Parkinson's in the lab
Jun 9 - A New Gene Has Been Linked to Parkinson's Disease
Jun 6 - A neurologist weighs in on Muhammad Ali's battle with Parkinson's disease